1. Introduction {#sec1}
===============

Gestational diabetes mellitus (GDM), which is defined as diabetes diagnosed in the second and third trimesters of pregnancy \[[@B1]\], has emerged as a global public health concern \[[@B2]\]. It has been associated with short-term and long-term adverse health outcomes for both mothers and their newborns \[[@B3]\]. Women with GDM are known to have decreased quality of life and increased risks of caesarean section, gestational hypertension, preeclampsia, and type 2 diabetes \[[@B4]--[@B7]\]. In babies, GDM has been found to be associated with macrosomia or larger than normal gestational-aged infants, neonatal hypoglycemia, and type 2 diabetes mellitus later in life \[[@B6], [@B8], [@B9]\]. As such, it is important to understand the burden of GDM in various parts of the world to provide country-specific information to help inform on policy and planning.

The global prevalence of GDM varies widely, from 1% to 28%, depending on population characteristics (e.g., maternal age, socioeconomic status, race/ethnicity, or body composition), screening methods, and diagnostic criteria \[[@B10]\]. In addition, as with the common form of type 2 diabetes \[[@B11]\], GDM can also be influenced by genetic factors, which may differently affect disease prevalence among populations \[[@B12]\]. To date, at least 8 associations have developed their own diagnostic criteria for GDM, namely, the American Diabetes Association (ADA 2004, 2007, 2010, and 2012), Australian Diabetes in Pregnancy Society (ADIPS), Carpenter-Coustan (CC), International Association of the Diabetes and Pregnancy Study Groups (IADPSG), International Classification of Diseases (ICD), Japan Society of Obstetrics and Gynecology (JSOG), National Diabetes Data Group (NDDG), and World Health Organization (WHO 1998, 1999, 2006, and 2013) \[[@B13], [@B14]\]. Data in high-income countries (HICs) ranges from 0.6% to 27.5% \[[@B15]\], and those in low- and middle-income countries are in the range of 0.4 and 24.3% \[[@B16]\]. Regional differences exist regarding the distribution of GDM, such as Africa and Asia, after adjusting the data with prevalence reports being 0%--13.9% and 1.6%--17.8%, respectively \[[@B17], [@B18]\].

Asia is the largest and most populated continent (60% of the world\'s population), with an increasing prevalence of GDM \[[@B19]\]. While maternal overweight/obesity is an established risk factor for GDM \[[@B20]\], particularly in HICs, recent reviews have found that the prevalence of GDM may be even higher among lean populations than those with a larger body size \[[@B2]\]. This is consistent with the developmental origins of adult disease hypothesis (DOHAD) as undernutrition in the first 1000 days is associated with later diabetes \[[@B21]--[@B24]\]. The Eastern and Southeastern subregions include 18 countries, with more than 30% of the Asian population \[[@B25]\] and contributing approximately 80% to the Asian economy \[[@B26]\]. Given the rapid socioeconomic and nutrition transition and the increasing prevalence of GDM in Asia \[[@B19], [@B27]\], it is of public health importance to provide an overview of this condition in Eastern and Southeastern Asia. However, accessible and systematically organized estimates of GDM prevalence in this subregion are lacking. Moreover, the lack of uniformity in screening methods, definition, and diagnostic criteria for GDM makes it difficult to compare the prevalence of GDM between and within countries. The aim of this study was to undertake a systematic review and meta-analysis of the prevalence and associated risk factors of GDM in selected countries of Eastern and Southeastern Asia.

2. Methods {#sec2}
==========

The present review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@B28]\] and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) protocols \[[@B29]\].

2.1. Search Strategy {#sec2.1}
--------------------

The databases (PubMed, Embase, and Scopus) were used to search relevant articles with the following key words: "gestational diabetes mellitus," "GDM," "hyperglycemia in pregnancy," "gestational hyperglycemia," or "diabetes in pregnancy" as well as "name of country" in Eastern and Southeastern Asia. The websites of the World Health Organization (WHO) and International Diabetes Federation were also reviewed to extend our search results. Then the reference lists of included articles were assessed to identify further relevant studies.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

Studies that met the following criteria were retrieved for assessment: (1) being conducted in Eastern and Southeastern Asian countries classified by the United Nations Statistics Division \[[@B30]\]; (2) being published in English language journals between January 1, 2000, and December 31, 2016; (3) reported primary results (i.e., original studies); (4) provided the prevalence of GDM and associated 95% confidence interval (CI) or total of participants and number of GDM events; and (5) had a sample size of at least 1000 and 50 GDM cases. When multiple publications were derived from analyses of the same or overlapping samples, we used data from the largest or most recent results only.

2.3. Study Selection {#sec2.3}
--------------------

Relevant papers identified from the aforementioned databases and websites were imported into an EndNote X7.5, and duplicates were removed. Two reviewers independently screened the titles and abstracts for potentially eligible articles based on the inclusion criteria. If a paper contained insufficient information on GDM in the title and/or abstract, the full text was retrieved for further assessment and any disagreement between the two reviewers was resolved through discussion. Finally, the full text of relevant studies was reviewed.

2.4. Quality Assessment and Data Extraction {#sec2.4}
-------------------------------------------

The guidelines of the National Health and Medical Research Council were used to assess the quality of searched articles by two independent investigators \[[@B31]\]. Only articles that meet the level III of evidence were included and analysed in this review. An extraction form was developed in Excel to record data from selected papers by one reviewer, and the completeness and accuracy of extracted data were verified by a second reviewer. The following characteristics were extracted from each study: first author, country, year of publication, year of survey, setting, gestational age, screening procedure (one and/or two steps), sample size, GDM cases, prevalence of GDM (including percentage and 95% CI), and diagnostic criteria for GDM. If 95% CIs were not reported, they were calculated based on the sample size and observed proportion of GDM in each selected study \[[@B32]\]. Since we only collected published studies, ethical approval was not required for this work.

2.5. Data Analysis {#sec2.5}
------------------

Diagnostic criteria were aggregated into 8 clusters due to some similarities: (1) JSOG, (2) NDDG, (3) ADA 2004/ADA 2010, (4) ICD10, (5) ADA 2007/CC, (6) WHO 1998--2006, (7) ADA 2012/IADPSG/WHO 2013; and (8) ADIPS98. The prevalences of GDM, with 95% CI, were grouped according to the different diagnostic criteria to perform meta-analyses. The summary prevalence (95% CI) regardless of and by each diagnostic criteria was calculated using the random effects model of the DerSimonian and Laird method \[[@B33]\] to allow for the possibility of real differences in the distribution of GDM between studies that are not solely resulted from sampling error. The heterogeneity among studies was tested with the *I* ^2^ index (low is \<25%, moderate 25%--50%, and high \> 50%), which describes the percent of total variation contributed by between-study variations \[[@B34]\]. The overall prevalence of GDM (95% CI) by each group of diagnostic criteria was depicted graphically in forest plots. Statistically significant heterogeneity was considered present at *P* \< 0.1 and *I* ^2^ \> 50% \[[@B35]\]. In addition, subgroup analysis according to lower- or upper-middle income countries (LMICs) or HICs, type of GDM screening, and individual country under study was performed to understand the impact of economic development and geographical location on the prevalence of GDM. The summary prevalence of GDM for each study that used more than one diagnostic criterion was pooled using a fixed effects model. All analyses were performed using Stata 13.1 (StataCorp LP, College Station, TX).

3. Results {#sec3}
==========

3.1. Description of Included Studies {#sec3.1}
------------------------------------

[Figure 1](#fig1){ref-type="fig"} shows the flow diagram of our systematic literature search. The initial search identified 5697 publications, and after the removal of duplicate records (*n* = 1282), 4415 were retrieved for preliminary assessment. Of these, 120 were potentially relevant after title and abstract screening, and thus, their full texts were obtained and evaluated against the inclusion criteria, resulting in 48 studies reported in 63 observations. No papers were retrieved from the reference list. Of 48 studies, one paper reported four values of GDM prevalence by using four diagnostic criteria \[[@B36]\], 12 papers had two values of GDM prevalence by comparing two different diagnostic criteria or screening types \[[@B37]--[@B48]\], and 35 papers only used one diagnostic criterion to estimate GDM prevalence \[[@B49]--[@B83]\].

3.2. Characteristics of Included Studies {#sec3.2}
----------------------------------------

The main characteristics of the included studies are described in the Supplemental Table (available [here](#supplementary-material-1){ref-type="supplementary-material"}). Between the years 2000 and 2016, 48 articles were published with a total sample of 3,594,803 pregnant women (range: 1038--1,824,913) in 7 countries. Of the 48 studies, 21 were conducted in China \[[@B41]--[@B43], [@B45], [@B48]--[@B64]\], 8 in the Republic of Korea \[[@B65], [@B68], [@B70]--[@B72], [@B74], [@B75], [@B77]\], 6 in Thailand \[[@B37], [@B46], [@B79]--[@B81], [@B83]\], five in Japan \[[@B39], [@B47], [@B73], [@B76], [@B78]\], five in Taiwan (China) \[[@B38], [@B44], [@B66], [@B67], [@B69]\], one in Malaysia \[[@B82]\], one in Singapore \[[@B40]\], and one in Vietnam \[[@B36]\]. Two-thirds of the studies (*n* = 32) used a two-step screening procedure, that is, women underwent a 1-hour glucose challenge test (GCT) and a 3-hour glucose tolerance test (GTT) if GCT were abnormal. To perform these tests, women were required to drink 50 g of glucose and 75 or 100 g of glucose for GCT and GTT, respectively. Over one-quarter of studies (*n* = 13) followed a single-step screening, where all pregnant women were given a 75 g GTT. Three studies did not specify the screening method used \[[@B56], [@B71], [@B75]\]. A total of 20 studies used IADPSG, the 2010 ADA, or the 2013 WHO standards as the GDM diagnostic criteria. The number of studies that employed CC or the 2007 ADA, NDDG, WHO (1998, 1999, and 2006) was 13, 12, and 10, respectively. The remaining 8 studies applied other criteria (see Supplemental Table). All studies included in the present review met the level III of evidence of the National Health and Medical Research Council in Australia \[[@B31]\].

3.3. Prevalence of GDM {#sec3.3}
----------------------

The overall mean prevalence of GDM, regardless of diagnostic standards, was 10.07 (95% CI: 6.47--15.68) ([Table 1](#tab1){ref-type="table"}). [Figure 2](#fig2){ref-type="fig"} depicts the prevalence of GDM across 8 diagnostic groupings. The highest prevalence of GDM was observed for studies using the IADPSG, ADA 2012, or WHO 2013 criteria (13.77%) while the lowest data was found among Japanese reports that employed JSOG criteria (2.80%). Between that range, the summary prevalence of GDM according to NDDG, ADA 2004 or ADA 2010, ADA 2007 or CC, and WHO (1998, 1999, or 2006) recommendations was 5.24%, 6.59%, 8.54%, and 9.40%, respectively. Only two single data points for GDM prevalence were reported using either ICD 10 \[[@B75]\] or ADIPS 1998 \[[@B36]\], with the respective prevalences being 7.53% and 20.82%, respectively ([Table 1](#tab1){ref-type="table"}). With the exception of studies employing JSOG, there was considerable heterogeneity of GDM prevalence among studies assessed based on various criteria; a measure of heterogeneity varied from 98.5% to 99.8% (*P* \< 0.001).

3.4. Prevalence of GDM by Income and Diagnostic Criteria {#sec3.4}
--------------------------------------------------------

Overall, the prevalence of GDM was higher in LMICs than HICs, 10.84% versus 6.66%, respectively ([Table 1](#tab1){ref-type="table"}). Except for pooled GDM prevalence according to WHO (1998, 1999, or 2006) criteria, the summary estimates of GDM prevalence based on other diagnostic criteria were greater in LMICs than in HICs. Notably, the prevalence using the most popular criteria, that is, ADA 2012, IADPSG, or WHO 2013, was over twofold higher in the former when compared with the corresponding figure in the latter (17.56% versus 7.48%) ([Table 1](#tab1){ref-type="table"}).

3.5. Prevalence of GDM by Screening Method {#sec3.5}
------------------------------------------

The mean prevalence of GDM derived using one-step screening and two-step screening was 15.71% (95% CI: 13.88--17.77%) and 7.15% (95%CI: 5.63--9.08%), respectively; there was substantial heterogeneity among studies using either the one-step screening method or the two-step screening method (*I* ^2^ \> 98% and *P* \< 0.001) ([Table 1](#tab1){ref-type="table"}).

3.6. Prevalence of GDM by Country {#sec3.6}
---------------------------------

There was variation in the overall prevalence of GDM, with Vietnam and Singapore showing the highest rates (20.06% and 18.93%, resp.). While mainland China and Malaysia had a comparable prevalence of GDM (11.91% and 11.83%), the remaining countries (Japan, Korea, Taiwan, and Thailand) had a GDM prevalence of less than 8.0%. It should be noted that mainland China accounted for nearly 50% of the total studies (*n* = 21) ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

The present review included 48 studies with more than three and a half million participants from 7 countries in Eastern and Southeastern Asia, showing a wide variation in the overall prevalence of GDM. The pooled prevalence of GDM was approximately 10%, with a higher estimate in LMICs than in HICs. The discrepancy in the overall estimate also existed according to diagnostic criteria and countries. The most widely used criteria were ADA 2012, IADPSG, or WHO 2013, resulting in a pooled prevalence of GDM of 14% while only a limited number of studies used ADIP 1998, ICD 10, JSOG, ADA 2004, or ADA 2010. The highest prevalence of GDM was found in Vietnam and Singapore, where approximately one in five women were diagnosed with GDM, followed by mainland China and Malaysia where about one in 9 women had GDM. The remaining countries had no more than one in 14 women with GDM. To the best of our knowledge, this is the first study that systematically synthesised data on the prevalence of GDM in important subregions of Asia, Eastern and Southeastern, and provided accessible evidence to formulate locally feasible strategies for effective and efficient prevention of GDM in Asia.

Overall, approximately one in 10 pregnant women in Eastern and Southeastern Asia had GDM. This finding is higher than African countries, where the average prevalence of GDM is about 6.0% \[[@B17]\]. Similarly, our data is greater than results reported in Western countries including Europe, US, and Australia, with the prevalence of GDM being 5.4%, 9.2%, and 5.7%, respectively \[[@B84]--[@B86]\]. We have no clear reason for such a discrepancy, but we speculate that it may be due to socioeconomic, racial/ethnic, or lifestyle disparities. For instance, Asian women were reportedly having a higher risk of GDM compared with their Caucasian, African-American, and Hispanic counterparts \[[@B87]\]. This observation suggests that the development of GDM may be shaped by early-life exposure to poor nutrition, that is, under- or overnutrition, and/or epigenetics according to the DOHAD theory \[[@B88]\]. Another factor may be the different screening regimes and testing methods that will be discussed below.

The lack of consensus regarding the use of diagnostic criteria for GDM is largely attributable to the heterogeneity of GDM prevalence. Of diverse diagnostic criteria such as NDDG \[[@B89]\], CC \[[@B90]\], ADA \[[@B91]\], and WHO \[[@B92]\], the IADPSG criteria based on the Hyperglycemia and Adverse Pregnancy Outcome Study (HAPO) has recently become more accepted \[[@B93]\]. Indeed, the use of IADPSG criteria may produce an estimated prevalence of GDM two to threefold even up to 7-fold higher than other criteria \[[@B13], [@B94]\]. In a Brazilian study, for instance, the prevalence of GDM was only 2.3% and 7.1% according to ADA 2010 and WHO 1999, respectively, but it increased to 18.0% following the IADPSG criteria \[[@B94]\]. An alternative explanation for the variation in GDM prevalence may be ascribed to different screening methods, that is, the one-step or two-step approach. Similar to our review, a recent meta-analysis of 40 studies in Europe reported that the one-step screening method resulted in a higher prevalence of GDM compared with the two-step procedure \[[@B86]\]. Although a one-step screening type is simpler, less laborious, and of low lost, it typically overestimates the prevalence of GDM \[[@B95]\]. However a two-step screening method is more accurate and could accordingly reduce personal and societal costs despite its inconvenience for patients and increased workload for healthcare professionals \[[@B96]\]. Given the lack of international consensus in screening and diagnostic methods for GDM, it is imperative to develop a standardised approach to allow for comparison of GDM burdens worldwide.

The high prevalences of GDM in less wealthy countries reviewed here are consistent with studies from other parts of Asia and Africa \[[@B17], [@B18]\]. Likewise, around 90% of cases of hyperglycemia during pregnancy occur in low- and middle-income nations as reported by the International Diabetes Federation in 2015 \[[@B27]\]. This discrepancy may be associated with limited access to maternal health care and/or low socioeconomic status in low- and middle-income economies \[[@B27], [@B97], [@B98]\]. It is evident from this review that the prevalence of GDM in Vietnam, a lower-middle income country, at least tripled the corresponding data in HICs such as Japan, Taiwan, and South Korea. It can also be speculated that the difference in lifestyle factors (e.g., diet and physical activity), acculturation, and urbanisation may explain the variation in GDM prevalence between the two aforementioned country-income groups \[[@B99]\]. This finding implies that improvement of socioeconomic conditions may contribute to the prevention of GDM.

On the other hand, more epidemiological studies on GDM in the remaining countries of Eastern and Southeastern Asian regions including Mongolia, Indonesia, Philippines, Myanmar, Cambodia, and Laos need to be conducted to add information to the current evidence. These studies should be performed in both urban and rural populations in order to compare and evaluate the effects of urbanisation on GDM in particular and public health in general.

The present review has the advantages of a large sample size with studies involving over three and a half million women, using different methods for screening and diagnosis of GDM and consistency of method, quality, and focus. There are several limitations that need to be considered when interpreting the results of this work. Our review indicated substantial heterogeneity of GDM prevalence across studies, making direct comparison difficult. Such variation may be attributable to the potential influence of screening procedures (i.e., selective or universal) for GDM and its diagnostic criteria, population characteristics, or other socioenvironmental factors. Nonetheless, those possible modifiers were not taken into account in this review due to the lack of data available from included studies. In addition, the inclusion of only English publications may have resulted in publication bias. Our review did not address GDM situations in other countries in the region including Indonesia, Philippines, Myanmar, Cambodia, and Laos due to the lack of data, and thus, the findings may not be generalisable to the whole Eastern and Southeastern Asia.

5. Conclusion {#sec5}
=============

A large-scale review of literature shows that around one in 10 pregnant women in Eastern and Southeastern Asia had GDM and the number of women with GDM varied substantially between and within countries. The prevalence of GDM was highest according to ADA 2012, IADPSG, or WHO 2013 criteria, greater following a one-step screening procedure and higher in LMICs. The findings suggest the need for developing an international uniformity regarding screening and diagnostic methods for GDM.
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![PRISMA flow diagram of selected studies.](JDR2018-6536974.001){#fig1}

![Forest plots presenting the prevalence of gestational diabetes for individual studies and the corresponding pooled prevalence for studies combined according to diagnostic criteria in Eastern and Southeastern Asia. Bars and diamonds indicate 95% confidence interval (CI). The size of each square corresponds to the weight of the study in the meta-analysis using the Der Simonian and Laird method. ADA: American Diabetes Association; CC: Carpenter-Coustan; IADPSG: International Association of the Diabetes and Pregnancy Study Groups; JSOG: Japan Society of Obstetrics and Gynecology; NDDG: National Diabetes Data Group; WHO: World Health Organization.](JDR2018-6536974.002){#fig2}

###### 

Pooled prevalence and 95% confidence interval of gestational diabetes according to the income group, screening type, and country.

                               Studies   Subjects    Prevalence   Lower 95% CI   Upper 95% CI   *I* ^2^   *P* ~heterogeneity~
  ---------------------------- --------- ----------- ------------ -------------- -------------- --------- ---------------------
  Income level                                                                                            
   High                                                                                                   
    JSOG                       2         3877        2.80         2.31           3.39           0.00%     0.411
    NDDG                       4         35,400      4.21         2.15           8.26           99.30%    \<0.001
    ICD10                      1         1,306,281   7.53         7.51           7.56           ---       ---
    ADA 2007/CC                9         1,880,183   7.38         6.03           9.03           98.90%    \<0.001
    WHO 1999--2006             2         2272        15.37        13.89          17.02          ---       ---
    ADA 2012/IADPSG/WHO 2013   6         16,237      7.48         4.74           11.80          98.60%    \<0.001
    Subtotal                   24        3,244,250   6.66         4.40           10.09          98.30%    \<0.001
   Lower- or upper-middle                                                                                 
    NDDG                       8         79,487      5.83         4.31           7.90           99.10%    \<0.001
    ADA 2004/ADA 2010          4         28,342      6.59         4.40           9.86           98.50%    \<0.001
    ADA 2007/CC                4         21,259      11.85        4.94           28.42          99.80%    \<0.001
    WHO 1999--2006             8         183,545     8.57         5.23           14.06          99.90%    \<0.001
    ADA 2012/IADPSG/WHO 2013   14        113,656     17.56        15.07          20.47          99.20%    \<0.001
    ADIPS98                    1         2772        20.82        19.34          22.40          ---       ---
    Subtotal                   39        429,061     10.84        7.35           15.99          94.40%    \<0.001
  Type of screening                                                                                       
   One step                    13        95,638      15.71        13.88          17.77          98.90%    \<0.001
   Two-step                    32        338,825     7.15         5.63           9.08           99.70%    \<0.001
   Unspecified                 3         3,132,329   7.83         7.39           8.29           99.70%    \<0.001
  Country                                                                                                 
   Mainland China              21        282,086     11.91        8.96           15.83          99.90%    \<0.001
   Japan                       5         12,596      6.08         3.49           10.62          98.70%    \<0.001
   Korea                       8         3,180,515   7.12         6.74           7.53           99.60%    \<0.001
   Malaysia                    1         1538        11.83        10.30          13.60          ---       ---
   Singapore                   1         1136        18.93        16.74          21.40          ---       ---
   Taiwan                      5         30,944      6.51         4.45           9.54           99.0%     \<0.001
   Thailand                    6         55,205      6.10         4.39           8.48           98.8%     \<0.001
   Vietnam                     1         2772        20.06        19.28          20.87          ---       ---
   All                         48        3,566,792   10.07        6.47           15.68          99.3%     \<0.001

---: not applicable; ADA: American Diabetes Association; ADIPS: Australian Diabetes in Pregnancy Society; CC: Carpenter-Coustan; IADPSG: International Association of the Diabetes and Pregnancy Study Groups; ICD: International Classification of Diseases; JSOG: Japan Society of Obstetrics and Gynecology; NDDG: National Diabetes Data Group; WHO: World Health Organization.
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